Neelapu SS, Locke FL, Bartlett NL, et al. Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). ASH 59th Annual Meeting & Exhibition, abstract 578.
Toediening AAV5-hFVIII-SQ geassocieerd met normalisatie factor VIII-activiteit
jan 2018 | Benigne hematologie